Previous case reports have linked RET fusions, such as CCDC6-RET, TRIM24-RET, NCOA4-RET and ERC1-RET, to osimertinib resistance in EGFR-mutated NSCLC patients [35–39]. Here, ERC1 is linked to non-small cell lung carcinoma.